logo

For the Inventor, By the Inventor

New York, NY, United States of America

Kadmon Corporation, LLC


USPTO Granted Patents = 21



Trademarks = 4

Forward Citations = 24

Loading Chart...
Loading Chart...

29 inventors (with patents filed for the assignee):

goldMedal Masha V Poyurovsky (11 out of 12 patents)

silverMedal Kevin G Liu (11 out of 16 patents)

bronzeMedal Ji-In Kim (10 out of 14 patents)

4.  Dan Lu (6 out of 10 patents)

5.  Zhenping Zhu (6 out of 10 patents)

6.  Alexandra Zanin-Zhorov (4 out of 5 patents)

7.  Kellen L Olszewski (4 out of 5 patents)

8.  Anthony Michael Barsotti (3 out of 5 patents)

9.  Koi Morris (3 out of 12 patents)

10.  Eduardas Skucas (3 out of 3 patents)

11.  Rigen Mo (3 out of 3 patents)

12.  Xuemei Yu (2 out of 2 patents)

13.  Samuel D Waksal (2 out of 4 patents)

14.  Zhanna Polonskaya (2 out of 2 patents)

15.  Jingya Zhang (2 out of 2 patents)


21 patents:

1. 12097202 - Methods of administering Belumosudil for treatment of chronic graft versus host disease (2024-09-24),
2. 12030857 - Glucose uptake inhibitors (2024-07-09),
3. 11952369 - Belumosudil metabolites and uses thereof in the treatment of chronic graft-versus-host disease (2024-04-09),
4. 11926596 - Inhibitors of Rho associated coiled-coil containing protein kinase (2024-03-12),
5. 11633475 - Human anti-VEGFR-2/KDR antibodies (2023-04-25),
6. 11613531 - Inhibitors of RHO associated coiled-coil containing protein kinase (2023-03-28),
7. 11479533 - Inhibitors of Rho associated coiled-coil containing protein kinase (2022-10-25),
8. 11311541 - Treatment of GVHD (2022-04-26),
9. 11071735 - Treatment of inflammatory conditions and autoimmune diseases with glucose uptake inhibitors (2021-07-27),
10. 10988484 - Glucose uptake inhibitors (2021-04-27),
11. 10729691 - Treatment of infectious diseases with glucose uptake inhibitors (2020-08-04),
12. 10696660 - Rho kinase inhibitors (2020-06-30),
13. 10588968 - Human anti-VEGFR-2/KDR antibodies (2020-03-17),
14. 10407502 - Immunomodulatory agents (2019-09-10),
15. 10364291 - Human anti-VEGFR-2/KDR antibodies (2019-07-30),
Kadmon Corporation is a biopharmaceutical company focused on developing innovative therapies for immune-related and oncology diseases. With a diverse pipeline of potential treatments, Kadmon strives to improve the lives of patients worldwide through its groundbreaking research and development efforts.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

...
21 Patents

#342 in New York, NY

#852 in New York

#15,183 in US

#29,080 in the World

...
New York, NY, United States of America

Kadmon Corporation, LLC

Forward Citations = 24

29 inventors:

goldMedal Masha V Poyurovsky (11 out of 12 patents)

silverMedal Kevin G Liu (11 out of 16 patents)

bronzeMedal Ji-In Kim (10 out of 14 patents)

4.  Dan Lu (6 out of 10 patents)

5.  Zhenping Zhu (6 out of 10 patents)

Please report any incorrect information to support@idiyas.com
Loading…